FGB: A Protein with Potential as A Drug Target and Biomarker (G2244)
FGB: A Protein with Potential as A Drug Target and Biomarker
FGB, also known as FGB variant 1, is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling.
FGB is characterized by its long, linear N-terminus, which contains a putative transmembrane domain and a single extracellular loop. It has been shown to interact with various signaling molecules, including GPCRs, phosphatidylinositol (PI) molecules, and GABA-Aminobutyric Acid ( GABA) receptors.
One of the most interesting aspects of FGB is its potential as a drug target. Its interaction with GPCRs and PI molecules suggests that FGB may play a role in modulating cellular signaling pathways, particularly those related to pain, inflammation, and neurodegenerative diseases.
FGB has also been shown to interact with GABA receptors, which are involved in the regulation of ion channels and neurotransmitter release. This suggests that FGB may have additional roles in modulating the activity of GABA-Aminobutyric Acid (GABA) receptors, which are involved in a variety of cellular processes, including mood regulation, learning, and memory.
Another potential function of FGB is its role in cell-cell adhesion. FGB has been shown to interact with the protein E-cadherin, which is involved in the formation of tight junctions and cell-cell adhesion. This suggests that FGB may play a role in regulating cell-cell adhesion, which is important for various cellular processes, including tissue repair and regeneration.
FGB has also been shown to be involved in a variety of signaling pathways related to inflammation and infection. Its interaction with GPCRs and PI molecules suggests that FGB may play a role in modulating the activity of signaling molecules involved in inflammation and infection, such as nuclear factor kappa B (NF-kappa-B) and the transcription factor-1 (TF-1).
In addition to its potential role in modulating cellular signaling pathways, FGB is also of interest as a potential biomarker. Its expression has been shown to be regulated by a variety of factors, including cytokines, chemokines, and growth factors. This suggests that FGB may be a useful marker for tracking changes in cellular signaling pathways, including those related to inflammation, pain, and neurodegenerative diseases.
Overall, FGB is a protein that has significant potential as a drug target and biomarker. Its interaction with GPCRs, PI molecules, and GABA receptors suggests that FGB may play a role in modulating cellular signaling pathways, including those related to pain, inflammation, and neurodegenerative diseases. Further research is needed to fully understand the functions of FGB and its potential as a drug and biomarker.
Protein Name: Fibrinogen Beta Chain
Functions: Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways
The "FGB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGB comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14 | FKBP15 | FKBP1A | FKBP1A-SDCBP2 | FKBP1B
